期刊文献+

本芴醇的合成工艺改进

Improvement of the Synthesis Process of Benfluorenol
原文传递
导出
摘要 以芴(2)为原料,经三氯异腈尿酸氯化得2,7-二氯芴(3),与氯乙酰氯发生酰化反应生成2,7-二氯芴-4-氯乙酮(4),再将还原、环合、胺化“一锅法”合成得到α-(二正丁胺甲基)-2,7-二氯-4-芴甲醇(5),最后与对氯苯甲醛缩合得到本芴醇(1),总收率36%,纯度99.4%。新工艺中的氯化采用三氯异腈尿酸为氯化剂,反应选择性与安全性提高;还原、环合与胺化运用“一锅法”完成,反应温度降低,反应周期缩短,生产效率提高(从60%提高到80%),适合放大生产。 Using fluorene(2)as the starting material,it was chlorinated by trichloroisocyanuric acid to obtain 2,7-dichlorofluorene(3),which was acylated with chloroacetyl chloride to produce 2,7-dichlorofluorene-4-chloroethyl ketone(4).Then,α-(di-n-butylaminomethyl)-2,7-dichloro-4-fluorenylmethanol(5)was obtained via reduction,cyclization and amination by one-pot method.Finally,5 was condensed with p-chlorobenzaldehyde to obtain benfluorenol(1),with an overall yield of 36%and a purity of 99.4%.The improved process used trichloroisocyanuric acid as the chlorinating agent,which improved the selectivity and safety of the reaction.The reduction,cyclization and amination were completed by onepot method,which reduced the reaction temperature,shortened the reaction cycle,improved production efficiency,and increased the yield from 60%to 80%.The improved process was simple to operate,low in production cost and suitable for industrial production.
作者 杨康 郑群 吴炜婷 陈旭香 赵建宏 YANG Kang;ZHENG Qun;WU Weiting;CHEN Xuxiang;ZHAO Jianhong(Engineering Research Center of Pharmaceutical Process Chemistry,Ministry of Education,School of Pharmacy,East China University of Science and Technology,Shanghai 200237)
出处 《中国医药工业杂志》 EI CAS CSCD 2024年第8期1089-1092,共4页 Chinese Journal of Pharmaceuticals
关键词 本芴醇 工艺改进 抗疟药 合成 benfluorenol process improvement antimalarial drug synthesis
  • 相关文献

参考文献3

二级参考文献40

  • 1WHO Expert Committee on the Selection and Use of Essential Medicines,"The selection and use of essential medicines (including the 12th Model List of Essential Medicines)", April 2002.
  • 2S Nwaka and RG Ridley. Virtual drug discovery and development for neglected diseases through public- private partnerships. Nature Reviews Drug Discovery,2003, Vol. 2, 919 ~ 928.
  • 3Peter B. Bloland,Drug resistance in malaria, WHO/CDS/CSR/DRS/2001.4.
  • 4WHO Malaria Control Department, IMPROVING THE AFFORDABILITY AND FINANCING OF ARTEMISININ - BASED COMBINATION THERAPIES, WHO/CDS/MAL/2003. 1095.
  • 5张礼和.文汇报[EB/OL].http://ww.cas.accn/html/dir/2003/02/28/7830. htm.,2003年2月28日.
  • 6WHO Technical Report No. 711, 1983.
  • 7Novartis, http: //www. malariaandhealth. com.
  • 8C. Souppart, N. Gauducheau, and N. Sandrenan, et al., Development and validation of a high- performance liquid chromatography- mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human plasma. Journal of Chromatography B,2002, 774:195 - 203.
  • 9P. Skelton -Stxoud, R. Mull, and The Novartis Co -Artemther International Development Team, Mededias Tropieals(Marseille), 1998,58:77 - 81.
  • 10C Falade, M Makanga, Z Premji, et al., Efficacy and safety of artemether - lumefantrine (Coartem(r)) tablets (six - dose regimen) in African infants and children with acute, uncomplicated falciparum malaria, submitted to the NEJM on November 28, 2003.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部